KRAS and cancer: Furthermore, consistent with the biochemical activity observed against multiple RAS variants and cellular pERK inhibition potency in RAS mutant cell lines, RMC-6236 caused potent growth inhibition of KRAS mutant cancer cell lines, exemplified by HPAC (KRASG12D/WT, PDAC) and Capan-2 (KRASG12V/WT, PDAC) with EC50 at 1.2 and 1.4 nmol/L, respectively (Supplementary Fig. S1B).